Osaka, Japan

Tetsuhiro Ogino


Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 340(Granted Patents)


Location History:

  • Nishinomiya, JP (2001)
  • Osaka, JP (2007 - 2012)

Company Filing History:


Years Active: 2001-2012

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Tetsuhiro Ogino: Innovator in Antiallergic Drug Development

Introduction

Tetsuhiro Ogino is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antiallergic agents. With a total of 5 patents to his name, Ogino's work has the potential to impact the treatment of allergic conditions.

Latest Patents

One of Ogino's latest patents is for an adenine compound and its use as a drug for topical administration. This innovative drug is designed to be effective as an antiallergic agent. The active ingredient in this formulation is an adenine compound represented by a specific general formula, which includes various structural components that enhance its efficacy. The compound can also exist as a pharmaceutically acceptable salt, broadening its application in medical treatments.

Career Highlights

Throughout his career, Tetsuhiro Ogino has worked with Dainippon Sumitomo Pharma Co., Ltd., where he has contributed to various research and development projects. His expertise in pharmaceutical sciences has allowed him to focus on creating effective treatments for allergy-related conditions.

Collaborations

Ogino has collaborated with notable coworkers such as Ayumu Kurimoto and Yoshiaki Isobe. These partnerships have likely enriched his research and development efforts, leading to innovative solutions in the pharmaceutical industry.

Conclusion

Tetsuhiro Ogino's contributions to the field of pharmaceuticals, particularly in the development of antiallergic drugs, highlight his role as an influential inventor. His work continues to pave the way for advancements in allergy treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…